Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: Field cancerization or contaminating tumor cells?

Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.
Breast Cancer Research and Treatment (Impact Factor: 3.94). 10/2012; 136(3). DOI: 10.1007/s10549-012-2290-3
Source: PubMed


Field cancerization effects as well as isolated tumor cell foci extending well beyond the invasive tumor margin have been described previously to account for local recurrence rates following breast conserving surgery despite adequate surgical margins and breast radiotherapy. To look for evidence of possible tumor cell contamination or field cancerization by genetic effects, a pilot study (Study 1: 12 sample pairs) followed by a verification study (Study 2: 20 sample pairs) were performed on DNA extracted from HER2-positive breast tumors and matching normal adjacent mammary tissue samples excised 1–3 cm beyond the invasive tumor margin. High-resolution molecular inversion probe (MIP) arrays were used to compare genomic copy number variations, including increased HER2 gene copies, between the paired samples; as well, a detailed histologic and immunohistochemical (IHC) re-evaluation of all Study 2 samples was performed blinded to the genomic results to characterize the adjacent normal tissue composition bracketing the DNA-extracted samples. Overall, 14/32 (44 %) sample pairs from both studies produced genome-wide evidence of genetic aberrations including HER2 copy number gains within the adjacent normal tissue samples. The observed single-parental origin of monoallelic HER2 amplicon haplotypes shared by informative tumor–normal pairs, as well as commonly gained loci elsewhere on 17q, suggested the presence of contaminating tumor cells in the genomically aberrant normal samples. Histologic and IHC analyses identified occult 25–200 μm tumor cell clusters overexpressing HER2 scattered in more than half, but not all, of the genomically aberrant normal samples re-evaluated, but in none of the genomically normal samples. These genomic and microscopic findings support the conclusion that tumor cell contamination rather than genetic field cancerization represents the likeliest cause of local clinical recurrence rates following breast conserving surgery, and mandate caution in assuming the genomic normalcy of histologically benign appearing peritumor breast tissue.

Electronic supplementary material
The online version of this article (doi:10.1007/s10549-012-2290-3) contains supplementary material, which is available to authorized users.

Download full-text


Available from: Anguraj Sadanandam, Jan 29, 2014
37 Reads
  • Source
    • "Low copy number gain of the ERBB2 gene and HER2 protein expression occurs in microscopically normal epithelial and mesenchymal cells from breasts of SBC patients Low copy number gain of the ERBB2 gene was the most common event among UMs with <105 Mb aberration load (Fig. 2, panels A1,A2) and the third most common change among all studied UMs (Table 1; Fig. 2, panels B1,B2). It has recently been suggested that the gain of ERBB2 in normal cells in the vicinity but outside the focus of primary tumor might represent an event related to infiltration of cancer cells into the normal parenchyma (Sadanandam et al. 2012). We therefore studied whether this aberration is present in microscopically normal epithelial cells, taking advantage of the large-format histopathology sections from Falun. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sporadic breast cancer (SBC) is a common disease without robust means of early risk prediction in the population. We studied 282 females with SBC, focusing on copy number aberrations in cancer-free breast tissue (uninvolved margin, UM) outside the primary tumor (PT). In total, 1162 UMs (1–14 per breast) were studied. Comparative analysis between UM(s), PT(s), and blood/skin from the same patient as a control is the core of the study design. We identified 108 patients with at least one aberrant UM, representing 38.3% of cases. Gains in gene copy number were the principal type of mutations in microscopically normal breast cells, suggesting that oncogenic activation of genes via increased gene copy number is a predominant mechanism for initiation of SBC pathogenesis. The gain of ERBB2, with overexpression of HER2 protein, was the most common aberration in normal cells. Five additional growth factor receptor genes (EGFR, FGFR1, IGF1R, LIFR, and NGFR) also showed recurrent gains, and these were occasionally present in combination with the gain of ERBB2. All the aberrations found in the normal breast cells were previously described in cancer literature, suggesting their causative, driving role in pathogenesis of SBC. We demonstrate that analysis of normal cells from cancer patients leads to identification of signatures that may increase risk of SBC and our results could influence the choice of surgical intervention to remove all predisposing cells. Early detection of copy number gains suggesting a predisposition toward cancer development, long before detectable tumors are formed, is a key to the anticipated shift into a preventive paradigm of personalized medicine for breast cancer.
    Genome Research 10/2015; 25(10). DOI:10.1101/gr.187823.114 · 14.63 Impact Factor
    • "00, No. 0, 1–12, 2015 numerous controversies and criticism [Euhus et al., 2002; Cavalli et al., 2004; Larson et al., 2005; Clarke et al., 2006; Larson et al., 2006; Ellsworth et al., 2010; Rennstam et al., 2010]. Specifically, genomic instability triggered by neoadjuvant therapy, contamination by tumor cells, and technical artifacts were considered the reasons for the apparent CNAs in nontumor mammary glandular tissue [Holliday et al., 2009; Rummel et al., 2012; Sadanandam et al., 2012]. In the current study, patients with any preoperative exposure to radio or chemotherapy were excluded. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Somatic mosaicism for DNA copy number alterations (SMC-CNAs) is defined as gain or loss of chromosomal segments in somatic cells within a single organism. As cells harboring SMC-CNAs can undergo clonal expansion, it has been proposed that SMC-CNAs may contribute to the predisposition of these cells to genetic disease including cancer. Herein, the gross genomic alterations (>500 kbp) were characterized in uninvolved mammary glandular tissue from 59 breast cancer patients and matched samples of primary tumors and lymph node metastases. Array based comparative genomic hybridization showed 10% (6/59) of patients harbored 1 - 359 large SMC-CNAs (mean: 1328 kbp; median: 961 kbp) in a substantial portion of glandular tissue cells, distal from the primary tumor site. SMC-CNAs were partially recurrent in tumors, albeit with considerable contribution of stochastic SMC-CNAs indicating genomic destabilization. Targeted resequencing of 301 known predisposition and somatic driver loci revealed mutations and rare variants in genes related to maintenance of genomic integrity: BRCA1 (p.Gln1756Profs*74, p.Arg504Cys), BRCA2 (p.Asn3124Ile), NCOR1 (p.Pro1570Glnfs*45), PALB2 (p.Ser500Pro) and TP53 (p.Arg306*). Co-occurrence of gross SMC-CNAs along with point mutations or rare variants in genes responsible for safeguarding genomic integrity highlights the temporal and spatial neoplastic potential of uninvolved glandular tissue in breast cancer patients. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Human Mutation 07/2015; 36(11):n/a-n/a. DOI:10.1002/humu.22845 · 5.14 Impact Factor
  • Source
    • "To analyze the spliced sB7-H3 in hepatoma and peritumor tissues, 25 of 50 HCC patients who had undergone surgical resection were enrolled. Solid hepatoma tissues and peritumor tissues were excised about 1 cm but no more than 3 cm away from the invasive tumor margin, as previously reported [27], [28]; samples were snap-frozen in liquid nitrogen for RNA extraction and subsequent cDNA synthesis. To analyze the influence of hepatoma on the level of spliced sB7-H3 in serum, 10 HCC patients who had undergone surgical resection were enrolled, and their sera obtained before resection and 2 weeks after were analyzed for spliced sB7-H3 by sandwich ELISA assay. "
    [Show abstract] [Hide abstract]
    ABSTRACT: B7-H3 is a recently discovered member of the B7 superfamily molecules and has been found to play a negative role in T cell responses. In this study, we identified a new B7-H3 isoform that is produced by alternative splicing from the forth intron of B7-H3 and encodes the sB7-H3 protein. Protein sequence analysis showed that sB7-H3 contains an additional four amino acids, encoded by the intron sequence, at the C-terminus compared to the ectodomain of 2Ig-B7-H3. We further found that this spliced sB7-H3 plays a negative regulatory role in T cell responses and serum sB7-H3 is higher in patients with hepatocellular carcinoma (HCC) than in healthy donors. Furthermore, we found that the expression of the spliced sb7-h3 gene is higher in carcinoma and peritumor tissues than in PBMCs of both healthy controls and patients, indicating that the high level of serum sB7-H3 in patients with HCC is caused by the increased expression of this newly discovered spliced sB7-H3 isoform in carcinoma and peritumor tissues.
    PLoS ONE 10/2013; 8(10):e76965. DOI:10.1371/journal.pone.0076965 · 3.23 Impact Factor
Show more